PRESS RELEASE published on 02/11/2025 at 07:30, 11 months 22 days ago Vente-unique.com boucle un 1er trimestre 2024-2025 record avec toujours une forte dynamique commerciale Le Groupe Vente-unique.com annonce un volume d'affaires global en hausse de 14,5% et un chiffre d'affaires consolidé en progression de 11,3% pour le 1er trimestre 2024-2025, confirmant sa confiance pour l'avenir E-commerce Chiffre D'affaires Croissance Europe Vente-unique.com
PRESS RELEASE published on 02/11/2025 at 07:30, 11 months 22 days ago Vente-unique.com achieves a record 1st quarter 2024-2025 with continued strong sales momentum Vente-unique.com reports strong Q1 results: 14.5% GMV growth to €66.6m, 11.3% revenue increase to €50.1m. Confident outlook for 2024-2025 Revenues Outlook Growth Q1 Results Vente-unique.com
PRESS RELEASE published on 02/11/2025 at 07:15, 11 months 22 days ago EQS-Adhoc: ams-OSRAM AG: ams OSRAM delivers cost savings ahead of plan, positive FCF in FY24, Q4 revenues & profitability above mid-point of guided range and expects FCF exceeding EUR 100m in 2025 ams OSRAM AG reports cost savings ahead of plan, positive FCF in FY24, and expects FCF exceeding EUR 100m in 2025. Q4 revenues & profitability above guided range. CEO anticipates improved profitability in FY25 Profitability Cost Savings Positive FCF Ams OSRAM AG Q4 Revenues
REGULATED PRESS RELEASE published on 02/11/2025 at 07:01, 11 months 22 days ago bioMérieux obtient l’autorisation de la FDA américaine pour la nouvelle version de son test moléculaire ciblant les causes de la gastroentérite, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid bioMérieux reçoit l'autorisation de la FDA américaine pour son test moléculaire BIOFIRE® FILMARRAY® Gastrointestinal Panel Mid ciblant la gastroentérite FDA BioMérieux BIOFIRE® Gastroentérite Test Moléculaire
REGULATED PRESS RELEASE published on 02/11/2025 at 07:01, 11 months 22 days ago bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid bioMérieux receives U.S. FDA clearance for the new version of its molecular test, the BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid, targeting causes of gastroenteritis. The test detects 11 common bacteria, viruses, and parasites from one sample in about 1 hour, improving patient outcomes BioMérieux FDA Clearance Gastroenteritis BIOFIRE® FILMARRAY® Molecular Test
PRESS RELEASE published on 02/11/2025 at 07:00, 11 months 22 days ago NORMA Group completes a challenging financial year 2024 with a stable level of profitability NORMA Group successfully concludes 2024 with stable profitability. Preliminary figures show sales of EUR 1.2 billion, adjusted EBIT at EUR 92.3 million, and strong cash flow. Divestment of Water Management business initiated Market Challenges Profitability 2024 Financial Results NORMA Group Divestment Process
PRESS RELEASE published on 02/11/2025 at 07:00, 11 months 22 days ago BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE BioVersys advances BV500 NTM program with continued support from CF AMR Syndicate, developing therapies for NTM lung disease in CF patients. Company focuses on antibacterial products against MDR bacteria BioVersys BV500 NTM Program CF AMR Syndicate NTM Lung Disease MDR Bacteria
PRESS RELEASE published on 02/11/2025 at 07:00, 11 months 22 days ago TUI Group: 10th consecutive quarter of Und. EBIT growth – Hotels, Cruises and TUI Musement driving improvement in FY25 Q1 TUI Group reports 10th consecutive quarter of underlying EBIT growth in FY25 Q1, driven by Hotels, Cruises, and TUI Musement. Q1 revenue up +13% to €4.9bn. Market + Airline segment shows 31% lower underlying EBIT due to investments for summer season Revenue Growth Underlying EBIT TUI Group FY25 Q1 Market + Airline
PRESS RELEASE published on 02/11/2025 at 07:00, 11 months 22 days ago Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Relief Therapeutics obtains European Patent Office grant for RLF-TD011, securing patent protection for epidermolysis bullosa treatment. Company advances wound care solution Relief Therapeutics European Patent Office Epidermolysis Bullosa Wound Treatment RLD-TD011
REGULATED PRESS RELEASE published on 02/11/2025 at 07:00, 11 months 22 days ago Biophytis dévoile ses perspectives stratégiques de l’année 2025 Biophytis dévoile ses perspectives stratégiques pour l’année 2025, incluant le lancement de nouveaux programmes cliniques et des collaborations clés dans le domaine des maladies liées à l'âge Stratégie Biophytis Partenariats Développement Clinique Maladies Liées À L'âge
Published on 02/06/2026 at 00:00, 5 minutes ago LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Published on 02/05/2026 at 23:00, 1 hour 5 minutes ago Grounded People Announces Non-Brokered Private Placement and Strategic Review
Published on 02/05/2026 at 21:00, 3 hours 5 minutes ago Kidoz Welcomes CloudX Innovation Driving Fairer Mobile Advertising Auctions
Published on 02/05/2026 at 18:50, 5 hours 15 minutes ago Athena Gold Provides Exploration Update From Nevada and Ontario
Published on 02/05/2026 at 19:27, 4 hours 38 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/05/2026 at 18:46, 5 hours 19 minutes ago EQS-Adhoc: Mayr-Melnhof Karton AG: Impairment requirements impact profit for the financial year 2025
Published on 02/05/2026 at 18:09, 5 hours 56 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/05/2026 at 17:55, 6 hours 10 minutes ago Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
Published on 02/05/2026 at 17:40, 6 hours 25 minutes ago BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 01.02.26.
Published on 02/05/2026 at 19:15, 4 hours 50 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/05/2026 at 19:15, 4 hours 50 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES JANVIER 2026
Published on 02/05/2026 at 19:15, 4 hours 50 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL